Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HarrowHROW +5.36%80 10-Year RORE % is 1.27 as of Jun. 2026. GuruFocus rates HROW with a GF Score™ of 80/100 and a GF Value™ of $42.00 (Fairly Valued). The stock has 4 warning signs investors should review. Among 668 Drug Manufacturers companies, Harrow ranks worse than 59.88% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Harrow's 10-Year RORE % for the quarter that ended in Jun. 2026 was 1.27%.
The industry rank for Harrow's 10-Year RORE % or its related term are showing as below:
HROW's 10-Year RORE % is ranked worse than 59.88% of 668
companies
in the Drug Manufacturers industry
Industry Median: 6.235
vs HROW: 1.27
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Harrow 10-Year RORE % Related Terms
Harrow 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for Harrow's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HROW vs XERS, PRGO, PAHC: 10-Year RORE % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Harrow's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harrow 10-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Harrow's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Harrow's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 10-year before.
Harrow (HROW) has a 10-Year RORE % of 1.27 as of Jun. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Harrow and its competitors. According to the industry distribution chart, Harrow ranks #400 out of 668 companies in the Drug Manufacturers industry, placing it in the top 59.9%.
Is Harrow's 10-Year RORE % too high?
Harrow's current 10-Year RORE % is 1.27. The Drug Manufacturers industry median 10-Year RORE % is 6.24. Harrow's value of 1.27 is 79.6% below this industry median. Based on the distribution chart, Harrow ranks #400 out of 668 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Harrow has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Harrow's 10-Year RORE % compare to XERS and PRGO?
According to the Drug Manufacturers industry distribution chart, Harrow ranks #400 out of 668 companies for 10-Year RORE %. This places Harrow in the lower half of its industry. The industry median 10-Year RORE % is 6.24. Harrow's value of 1.27 is 79.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Drug Manufacturers company?
The median 10-Year RORE % among Drug Manufacturers companies is 6.24, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harrow's current 10-Year RORE % of 1.27 is 79.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Harrow and its competitors. For the Drug Manufacturers industry, the median 10-Year RORE % is 6.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harrow's current 10-Year RORE % is 1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harrow stock overvalued right now?
Based on GuruFocus' analysis, Harrow (HROW) is currently considered Fairly Valued. The stock's GF Value™ is $42.00, compared to a current price of $41.63 — trading 0.9% below its estimated fair value. The current 10-Year RORE % is 1.27 and 79.6% below the Drug Manufacturers industry median of 6.24. Harrow's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Harrow (HROW), the current 10-Year RORE % is 1.27 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harrow (HROW) Overvalued in 2026?
Based on GuruFocus' analysis, Harrow stock appears to be undervalued.
The current stock price of $41.63 is trading 0.9% below its estimated GF Value™ of $42.00.
GuruFocus considers Harrow to be Fairly Valued.
Key valuation signals for HROW:
10-Year RORE %: 1.27
GF Value™: $42.00 vs. price of $41.63 (0.9% below fair value)
Industry Position: 79.6% below the Drug Manufacturers median (#400 of 668)
No single metric tells the full story. See the HROW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
80GF Score
Get the complete analysis for HROW
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HROW has been successfully added to your 
